FDA Requires Single Packs for Kid-Safe Dissolving Meds
Published Date: 6/5/2025
Notice
Summary
The FDA wants to make sure certain over-the-counter medicines that dissolve in your mouth come in single-use packages. This change helps keep doses safe and easy to use, especially for kids and busy folks. If this rule passes, drug makers will need to update their packaging soon, which might cost a bit but will make medicine safer for everyone.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Single‑Use Packaging for ODT/Film Drugs
If finalized, the FDA will require over-the-counter drugs that dissolve in your mouth (orally disintegrating tablets and films) to be packaged in single‑unit or unit‑dose containers. You may see drug makers update packaging soon, which the agency says will help keep doses safe and easy to use for consumers, including children and busy people.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-10252, Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs
The FDA is making it easier for companies to switch certain OTC pills into chewable tablets, dissolving tablets, or films without extra paperwork. This helps drug makers update their products faster while keeping safety rules in check. If approved, these minor changes could save time and money for everyone involved.
Next: 2025-10254, Notice of Public Meeting of the Montana Advisory Committee to the U.S. Commission on Civil Rights
The Montana Advisory Committee to the U.S. Commission on Civil Rights is holding a public Zoom meeting on June 26, 2025, at 2 p.m. MT. They’ll talk about important civil rights issues affecting people in Montana. This is a chance for the community to stay informed and involved—no cost to join, just show up online!